secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ernexa Therapeutics Inc. (ERNA)
CIK:        0000748592
Form:       8-K
Filed at:   2025-07-07T23:59:59+00:00
Accession:  0001641172-25-018009
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ernexa Therapeutics dismisses Grant Thornton, appoints Haskell & White as auditor
--------------------------------------------------------------------------------

- Dismissal of Grant Thornton effective June 30, 2025; appointment of Haskell & White effective July 1, 2025, approved by Audit Committee.
- Grant Thornton's reports for FY 2023 and 2024 included a going-concern explanatory paragraph but were otherwise unqualified.
- No disagreements with Grant Thornton; only disclosed material weakness in FY 2023 internal controls from lack of technical accounting proficiency.
- Grant Thornton provided a letter to the SEC regarding the dismissal, attached as Exhibit 16.1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/748592/000164117225018009/0001641172-25-018009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/748592/000164117225018009/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-018009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer